Here, an erythrocyte membrane‐camouflaged nanodrug delivery system (TR‐ZRA) modified with transferrin receptor aptamers that can be targeted across the blood–brain barrier to ameliorate AD immune environment is established. This evidence concerns the gene TFRC and Alzheimer disease.